Worth Watching Stocks in Focus: Dow Chemical Co (NYSE:DOW), Novartis AG (ADR) (NYSE:NVS)

On Wednesday, Shares of Dow Chemical Co (NYSE:DOW), subtract -0.48% and shut at $54.07 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $53.89 and $54.36. Howard Ungerleider, Vice Chairman and Chief Financial Officer of The Dow Chemical Company (DOW), will present at Citi’s 2016 Basic Materials Conference in New York, NY at 8:45 a.m. (EST), November 29.

Ungerleider will highlight Dow’s ongoing financial performance in addition to progress against its priorities and planned growth investments.

Shares of Novartis AG (ADR) (NYSE:NVS), added 1.06% and shut at $68.81 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $67.28 and $68.83. The association’s commercial center capitalization is $181.49 Billion with the general uncommon loads of 2.38 billion. Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, counting ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates mainly antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, in addition to biotechnology manufacturing services to other companies.

Leave a Reply

Your email address will not be published. Required fields are marked *